OncoMatch/Clinical Trials/NCT05345613
Tranexamic Acid During Colonic Endoscopic Resection Procedures
Is NCT05345613 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Tranexamic acid and Standard for colon neoplasm.
Treatment: Tranexamic acid · Standard — Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.
Check if I qualifyEligibility summary
For patients with Colon Carcinoma.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify